Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.
Sugarman S, Wasserheit C, Hodgman E, Coglianese M, D'Alassandro A, Fornier M, Troso-Sandoval T, D'Andrea G, Drullinsky P, Lake D, George R, Mills N, Moynahan M, Smith J, Panageas K, Norton L, Hudis C. Sugarman S, et al. Among authors: d alassandro a, lake d, d andrea g. Breast Cancer Res Treat. 2009 Jun;115(3):609-12. doi: 10.1007/s10549-008-0152-9. Epub 2008 Aug 27. Breast Cancer Res Treat. 2009. PMID: 18751888 Clinical Trial.
Aromatase inhibitors in breast cancer: an update.
Lake DE, Hudis C. Lake DE, et al. Cancer Control. 2002 Nov-Dec;9(6):490-8. doi: 10.1177/107327480200900606. Cancer Control. 2002. PMID: 12514567 Free article. Review.
High-dose chemotherapy in breast cancer.
Lake DE, Hudis CA. Lake DE, et al. Drugs. 2004;64(17):1851-60. doi: 10.2165/00003495-200464170-00001. Drugs. 2004. PMID: 15329034 Review.
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
Dang CT, D'Andrea GM, Moynahan ME, Dickler MN, Seidman AD, Fornier M, Robson ME, Theodoulou M, Lake D, Currie VE, Hurria A, Panageas KS, Norton L, Hudis CA. Dang CT, et al. Among authors: d andrea gm, lake d. Clin Cancer Res. 2004 Sep 1;10(17):5754-61. doi: 10.1158/1078-0432.CCR-04-0634. Clin Cancer Res. 2004. PMID: 15355903 Clinical Trial.
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.
Fornier MN, Seidman AD, Lake D, D'Andrea G, Bromberg J, Robson M, Van Poznak C, Panageas KS, Atienza M, Norton L, Hudis C. Fornier MN, et al. Among authors: lake d, d andrea g. Clin Cancer Res. 2007 Jan 1;13(1):223-7. doi: 10.1158/1078-0432.CCR-06-1731. Clin Cancer Res. 2007. PMID: 17200358 Clinical Trial.
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Traina TA, Poggesi I, Robson M, Asnis A, Duncan BA, Heerdt A, Dang C, Lake D, Moasser M, Panageas K, Borgen P, Norton L, Hudis C, Dickler MN. Traina TA, et al. Among authors: lake d. Breast Cancer Res Treat. 2008 Sep;111(2):377-88. doi: 10.1007/s10549-007-9787-1. Epub 2007 Oct 20. Breast Cancer Res Treat. 2008. PMID: 17952589 Clinical Trial.
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Dang C, Fornier M, Sugarman S, Troso-Sandoval T, Lake D, D'Andrea G, Seidman A, Sklarin N, Dickler M, Currie V, Gilewski T, Moynahan ME, Drullinsky P, Robson M, Wasserheit-Leiblich C, Mills N, Steingart R, Panageas K, Norton L, Hudis C. Dang C, et al. Among authors: lake d, d andrea g. J Clin Oncol. 2008 Mar 10;26(8):1216-22. doi: 10.1200/JCO.2007.12.0733. J Clin Oncol. 2008. PMID: 18323546 Clinical Trial.
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C. Seidman AD, et al. Among authors: lake d. J Clin Oncol. 2008 Apr 1;26(10):1642-9. doi: 10.1200/JCO.2007.11.6699. J Clin Oncol. 2008. PMID: 18375893 Clinical Trial.
454 results